Biogen Reports New Spinraza Data in SMA

Biogen reported initial data from the Spinraza clinical development program that examined using higher doses of the therapy to optimize outcomes for people with the rare neurodegenerative condition spinal muscular atrophy, which supports continued development of the higher dose regimen.